公开(公告)号：US11377444B2

公开(公告)日：2022-07-05

申请号：US16760740

申请日：2018-11-02

申请人： MEDSHINE DISCOVERY INC.

发明人： Kevin X Chen ,  Zhaoguo Chen ,  Li Zhang ,  Yanxin Yu ,  Kai Zhou ,  Boyu Hu ,  Xiaofei Wang ,  Guoping Hu ,  Jian Li ,  Shuhui Chen

IPC分类号： C07D471/04 ,  A61P35/00 ,  C07D519/00

摘要： Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

公开(公告)号：US11066411B2

公开(公告)日：2021-07-20

申请号：US16500901

申请日：2018-04-08

申请人： MEDSHINE DISCOVERY INC.

发明人： Kevin X Chen ,  Yanxin Yu ,  Xinde Chen ,  Li Zhang ,  Zhaoguo Chen ,  Cheng Xie ,  Xiaofei Wang ,  Linghui Wu ,  Guoping Hu ,  Jian Li ,  Shuhui Chen

IPC分类号： C07D487/04 ,  A61P25/16 ,  A61P35/00

摘要： Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.

公开(公告)号：US20220267310A1

公开(公告)日：2022-08-25

申请号：US17622522

申请日：2020-06-24

申请人： MEDSHINE DISCOVERY INC.

发明人： Kevin X Chen ,  Zhaoguo Chen ,  Li Zhang ,  Boyu Hu ,  Shuhui Chen

IPC分类号： C07D413/14 ,  A61P35/00

摘要： Disclosed in the present invention are a compound as represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof, and disclosed is an application thereof in preparing drugs for treating DNA-PK inhibitor-related diseases.

公开(公告)号：US11117899B2

公开(公告)日：2021-09-14

申请号：US16500901

申请日：2018-04-08

申请人： MEDSHINE DISCOVERY INC.

发明人： Kevin X Chen ,  Yanxin Yu ,  Xinde Chen ,  Li Zhang ,  Zhaoguo Chen ,  Cheng Xie ,  Xiaofei Wang ,  Linghui Wu ,  Guoping Hu ,  Jian Li ,  Shuhui Chen

IPC分类号： C07D487/04 ,  A61P25/16 ,  A61P35/00

摘要： Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.

公开(公告)号：US12030897B2

公开(公告)日：2024-07-09

申请号：US17053076

申请日：2019-05-08

申请人： MEDSHINE DISCOVERY INC.

发明人： Kevin X Chen ,  Fen Jiang ,  Xinde Chen ,  Li Zhang ,  Zhaoguo Chen ,  Yanxin Yu ,  Kai Zhou ,  Boyu Hu ,  Cheng Xie ,  Shuhui Chen

IPC分类号： C07D519/00 ,  A61P35/00

CPC分类号： C07D519/00 ,  A61P35/00

摘要： The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11639355B2

公开(公告)日：2023-05-02

申请号：US16979202

申请日：2019-03-12

申请人： LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD. ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. ,  MEDSHINE DISCOVERY INC.

发明人： Kevin X Chen ,  Xiaobing Yan ,  Jianglei Huang ,  Yuekun Nie ,  Guoping Hu ,  Jian Li ,  Shuhui Chen ,  Jiaqiang Dong ,  Tie-Lin Wang

IPC分类号： C07D239/22 ,  C07D487/04 ,  A61P35/00 ,  C07D519/00

摘要： Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.

公开(公告)号：US11466024B2

公开(公告)日：2022-10-11

申请号：US16635916

申请日：2018-07-27

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  MEDSHINE DISCOVERY INC.

发明人： Kevin X Chen ,  Kai Zhou ,  Yanxin Yu ,  Boyu Hu ,  Linghui Wu ,  Xiaoyuan Chen ,  Jiangfeng Lin ,  Haomin Chen ,  Xiangjian Wang ,  Xiquan Zhang ,  Xin Tian ,  Hongjiang Xu

IPC分类号： C07D495/04

摘要： A bicyclic compound acting as a RORγ inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good RORγ inhibitory activities, being expected to be used for treating diseases mediated by RORγ receptors in a mammal.